Cargando…
Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature
BACKGROUND: Oxaliplatin is a platinum compound used in the treatment of gastrointestinal malignancies, including colorectal cancer. The incidence of hypersensitivity reaction in patients receiving oxaliplatin is approximately 15%, with severe reaction (grade 3 and 4) occurring in 2% of patients. CAS...
Autores principales: | Bautista, Marnelli A, Stevens, W Tait, Chen, Chien-Shing, Curtis, Brian R, Aster, Richard H, Hsueh, Chung-Tsen |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859393/ https://www.ncbi.nlm.nih.gov/pubmed/20346128 http://dx.doi.org/10.1186/1756-8722-3-12 |
Ejemplares similares
-
A case of oxaliplatin-induced immune-mediated thrombocytopenia
por: Suh, Seong Eun, et al.
Publicado: (2014) -
Pancytopenia associated with clonazepam
por: Bautista-Quach, Marnelli A, et al.
Publicado: (2010) -
Antiplatelet antibodies in oxaliplatin-induced immune thrombocytopenia
por: Mittal, Kriti, et al.
Publicado: (2014) -
Hypersensitivity reactions related to oxaliplatin (OHP)
por: Brandi, G, et al.
Publicado: (2003) -
Oxaliplatin-Related Hypersensitivity Reactions: A Single Institution Series and Literature Review
por: Barbin, Francesca, et al.
Publicado: (2022)